We develop and manufacture diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. We also develop and manufacture adeno-associated viral vectors, lenti viral vectors and retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house.
Advanced Therapies Europe promises to educate and inspire advanced therapies professionals currently working in Europe, as well as those that are looking to enter into the European market.
Advanced Therapies Europe is tailored to a European audience looking to commercialize ATMPs globally, as well as a global audience looking to understand and expand into the European market. By bringing these two groups together, new partnerships can be forged to solidify Europe as a hub for cell and gene therapy.